Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and China, has announced that the US Food and Drug Administration (FDA) has granted fast-track designation for its investigational drug ²²⁵Ac-FL-020 for the treatment of metastatic castration resistant prostate cancer (mCRPC).
²²⁵Ac-FL-020 is a PSMA-targeted radionuclide drug conjugate (RDC) with the potential to be best-in-class. In preclinical models, radiolabeled FL-020 has demonstrated superior in vivo distribution characteristics, including high levels and sustained tumor uptake, coupled with rapid systemic clearance. In the LNCaP xenograft mouse model, ²²⁵Ac-FL-020 has shown promising anti-tumor activity and a favorable safety profile. The drug was cleared for clinical trials in the US in May this year.- Flcube.com
